NHS Supply Chain

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

Retrieved on: 
Tuesday, October 17, 2023
NHS Supply Chain, ElectroCore, ECOR, United, Nerve conduction study, NHS, Business, Supply chain, Patient, Medical device

ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National Health Service (NHS) Supply Chain catalogue for an additional two years through March 17, 2026.

Key Points: 
  • ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National Health Service (NHS) Supply Chain catalogue for an additional two years through March 17, 2026.
  • The listing, which commenced on June 4, 2019, was scheduled to terminate on March 18, 2024.
  • “We are delighted the NHS Supply Chain intends to continue to include the gammaCore device within their framework agreement, commencing March 2024 through March 2026 with an option to extend for a further 2 years,” stated Mitch DeShon, Vice President of Global Sales & Business Development at electroCore.
  • “Inclusion in this catalogue helps ensure gammaCore therapy is broadly accessible to patients across the UK who may benefit from non-invasive vagus nerve stimulation and adds increased validation to the benefits realized by patients in the UK using gammaCore therapy.”

NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff

Retrieved on: 
Wednesday, September 27, 2023
Medical Devices, Health, Apps, Applications, Technology, General Health, Hardware, Infection, Partnership, Marketing, SAW, NHS Supply Chain, Patient, Drug Tariff, NHS, Catheter-associated urinary tract infection, Pharmaceutical industry, Health insurance

NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its application for UroShield actuators to be available on NHS Prescription Services’ Drug Tariff has been approved.

Key Points: 
  • NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its application for UroShield actuators to be available on NHS Prescription Services’ Drug Tariff has been approved.
  • Drug Tariff provides for full reimbursement of UroShield actuators by the NHS.
  • Clinicians in the U.K. will be able to prescribe the products, which are used in conjunction with the UroShield device, beginning November 1, 2023.
  • Both hospital and community clinicians will have the option of prescribing UroShield either through the prescription process or through the NHS contract.

NanoVibronix Issues Letter to Shareholders

Retrieved on: 
Thursday, May 18, 2023
General Health, Health, Medical Devices, CMS, Centers for Medicare & Medicaid Services, SAW, NHS Supply Chain, Medicare, COVID-19, Patient, Veterans Health Administration, Growth, Pharmaceutical industry

NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter 2023 and recent business developments.

Key Points: 
  • NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter 2023 and recent business developments.
  • NanoVibronix is committed to our strategic vision of commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase value for our shareholders.
  • We are focused on several areas, which we believe will have a substantial impact on our growth and product adoption.
  • As a result, CMS has invited NanoVibronix to a public meeting to present our findings and to answer CMS’s questions, which is scheduled to be held on June 1, 2023.

Unipart announces 2022 financial results

Retrieved on: 
Thursday, April 27, 2023
Heart, Partnership, Princess Royal, Hydrotreated vegetable oil, Culture, NHS Supply Chain, HVO, JCB, Recycling, Carbon, OXFORD, Philosophy, Gold, Lotus Evija, Growth, NHS, Courage, Jaguar Land Rover, Safety, Lotus, Automotive industry, Cryptocurrency, Management, Renewable energy, Airline, Electric battery, Agriculture, Nursing, Unipart, Airbus

Significant business growth in 2022 contributed to Unipart's positive financial results.

Key Points: 
  • Significant business growth in 2022 contributed to Unipart's positive financial results.
  • "Despite the global challenges affecting economies and supply chains, 2022 was a positive year for Unipart, with double-digit revenue and earnings growth across our business.
  • In 2022, Unipart measured its full carbon footprint for the first time, including emissions from the entire value chain.
  • Unipart was also named 'Corporation of the Year' at the 2022 Automotive Global Awards for its innovative electric vehicle proposition.

Unipart announces 2022 financial results

Retrieved on: 
Thursday, April 27, 2023
Heart, Partnership, Princess Royal, Hydrotreated vegetable oil, Culture, NHS Supply Chain, HVO, JCB, Recycling, Carbon, OXFORD, Philosophy, Gold, Lotus Evija, Growth, NHS, Courage, Jaguar Land Rover, Safety, Lotus, Automotive industry, Cryptocurrency, Management, Renewable energy, Airline, Electric battery, Agriculture, Nursing, Unipart, Airbus

Significant business growth in 2022 contributed to Unipart's positive financial results.

Key Points: 
  • Significant business growth in 2022 contributed to Unipart's positive financial results.
  • "Despite the global challenges affecting economies and supply chains, 2022 was a positive year for Unipart, with double-digit revenue and earnings growth across our business.
  • In 2022, Unipart measured its full carbon footprint for the first time, including emissions from the entire value chain.
  • Unipart was also named 'Corporation of the Year' at the 2022 Automotive Global Awards for its innovative electric vehicle proposition.

NanoVibronix Issues Letter to Shareholders

Retrieved on: 
Tuesday, April 18, 2023
Health Technology, Health, Medical Devices, Partnership, Rib cage, Tetraplegia, Negotiation, SAW, NHS Supply Chain, Infection, COVID-19, Quality of life, Accomplishment, Pain, Patient, Royal National Orthopaedic Hospital, United Kingdom, Third party, NHS, FDA, University of Southampton, Nursing, Pharmaceutical industry, Health insurance

NanoVibronix, Inc ., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a year in review and vision for 2023.

Key Points: 
  • NanoVibronix, Inc ., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a year in review and vision for 2023.
  • NanoVibronix is committed to our strategic vision of commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase value for our shareholders.
  • With all of the positive feedback we receive, it is clear that we are making a difference.
  • NanoVibronix entered 2022 on a high note, with the previous quarter’s revenue at an all-time high and two contracts with significant quantity minimums.

Research by IT Enterprise Business Solutions reveals 61% of medical equipment delays throughout NHS are caused by global component shortages

Retrieved on: 
Tuesday, February 28, 2023
NHS Supply Chain, Delays, Research, ICNS, NHS, SME, Medical device, Birth control

LONDON, Feb. 28, 2023 /PRNewswire/ -- A recent study by IT Enterprise Business Solutions, the UK's leading business software solutions provider for SMEs, has revealed that global component shortages account for over 60% of the NHS's medical equipment delays. The research also found that the number of delays peaks between 30 and 60 days at 22% before dropping significantly to just over 1% between 90 and 120 days.

Key Points: 
  • LONDON, Feb. 28, 2023 /PRNewswire/ -- A recent study by IT Enterprise Business Solutions , the UK's leading business software solutions provider for SMEs, has revealed that global component shortages account for over 60% of the NHS's medical equipment delays.
  • Researchers also found that 98% of delays above 120 days were caused by increased demand.
  • Breaking down delay by equipment type reveals that 25% correspond to general healthcare products, 17% to tubing, and 9% to dressings.
  • Delays of most items seem to happen in the 30-to-60-day mark with general supply and global components being the major causes.

NanoVibronix Announces Partnership with Peak Medical, Ltd.

Retrieved on: 
Tuesday, December 13, 2022
Managed Care, General Health, Medical Devices, Hospitals, Other Manufacturing, Health Technology, Transport, Medical Supplies, Practice Management, Manufacturing, Logistics, Supply Chain Management, Health, NHS, Security (finance), National Health Service (England), SAW, United Kingdom, Risk, Commercial, NHS Supply Chain, Nursing, Patient, Sale, Biofilm, Research, Hospital, Incidence, Quality of life, COVID-19, Clinical trial, NICE, XV, Marketing, Infection, National Health Service, Pharmaceutical industry, Medical imaging

We are enthusiastic about partnering with Peak Medical, a company that provides first class products and services for catheter and continence care to NHS hospitals and communities throughout the United Kingdom, stated Brian Murphy, Chief Executive Officer of NanoVibronix.

Key Points: 
  • We are enthusiastic about partnering with Peak Medical, a company that provides first class products and services for catheter and continence care to NHS hospitals and communities throughout the United Kingdom, stated Brian Murphy, Chief Executive Officer of NanoVibronix.
  • Peak Medical has a management team with vast experience in urological medicine leading a team of significant sales and marketing resources with strong distribution capabilities throughout the UK and Ireland.
  • Paul Newman, Commercial Director of Peak Medical Ltd., commented, We anticipate a strong uptake of UroShield given patient demand for the device in the National Health Service.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at: http://www.sec.gov .

SpectrumX’s Hand Sanitiser Approved for NHS Supply Chain’s NHS Supplier List

Retrieved on: 
Thursday, December 1, 2022
Pharmaceutical, Health, Medical Supplies, RADIUS, NHS Supply Chain, Skin, London Stock Exchange, Hypochlorous acid, Degenerative disease, GP, Clostridium difficile, Trust law, Bacteria, Health, Plastic, Spore, Fungus, IPO, London, Letter, Interest, Virus, Yeast, Water, Hand washing, NHS, Human, Infection, Pharmaceutical industry, Health insurance, Vaccine, Tuberculosis

As a result, SpectrumX will be awarded a tender framework agreement to become an approved NHS supplier, allowing NHS healthcare facilities to purchase the Companys patent-pending hand sanitiser.

Key Points: 
  • As a result, SpectrumX will be awarded a tender framework agreement to become an approved NHS supplier, allowing NHS healthcare facilities to purchase the Companys patent-pending hand sanitiser.
  • NHS Supply Chain is a logistics company that manages the sourcing, delivery, and supply of healthcare and food products to the NHS and other healthcare organisations in England and Wales.
  • Buyers and procurement teams at NHS Trusts, GP and dentistry surgeries, care homes, and other facilities purchase through the NHS Supply Chain catalogue.
  • Damien Hancox, CEO of SpectrumX, said: We are thrilled that weve succeeded, through this rigorous tender process, in becoming an approved NHS supplier with NHS Supply Chain.

NanoVibronix Provides Business Update in Letter to Shareholders

Retrieved on: 
Tuesday, November 15, 2022
Biotechnology, Health Technology, Health, Medical Devices, FDA, Sale, CMS, Marketing, Clinical trial, United Kingdom, NHS Supply Chain, Risk, Trademark dilution, Engineering, Insurance, Life expectancy, SAW, Letter, Research, Kaweah Delta Medical Center, Security (finance), WCI, Regulation of tobacco by the U.S. Food and Drug Administration, Biofilm, University of Southampton, TPA, Food, Patient, Pharmaceutical industry, Medicaid, Medicare

NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided the following business update in a letter to shareholders from its Chief Executive Officer, Brian Murphy:

Key Points: 
  • NanoVibronix, Inc. , (NASDAQ: NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided the following business update in a letter to shareholders from its Chief Executive Officer, Brian Murphy:
    Today, I would like to provide you with an update on the progress we are making towards scaling our business and unlocking the full value of our products.
  • We continue to believe that our vision for a fully commercialized portfolio of distinct and effective therapies will be realized.
  • The long-term investment thesis for our business remains unchanged despite elongated regulatory approvals and near-term challenges we are working to overcome.
  • While at the conference we met with several prospective TPA customers who have needs for pain resolution products for their patients.